المؤلفون: Jingran Ji, MD, Jacqueline V. Aredo, MD, MS, Andrew Piper-Vallillo, MD, Laura Huppert, MD, Julia K. Rotow, MD, Hatim Husain, MD, Susan Stewart, PhD, Rosemary Cobb, BS, Heather A. Wakelee, MD, Collin M. Blakely, MD, PhD, Melisa L. Wong, MD, MAS, Matthew A. Gubens, MD, MS, Mohammad H. Madani, MD, Subba R. Digumarthy, MD, Caroline McCoach, MD, PhD, Zofia Piotrowska, MD, MHS, Joel W. Neal, MD, PhD, Jonathan W. Riess, MD, MS

المصدر: JTO Clinical and Research Reports, Vol 4, Iss 3, Pp 100459- (2023)

مصطلحات موضوعية: Osimertinib, Non–small cell lung cancer, Atypical EGFR mutation, L861Q, G719X, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364322001849; https://doaj.org/toc/2666-3643

URL الوصول: https://doaj.org/article/0cd8922ebf5946adba6b0fb71a9d9100

المؤلفون: Ambrx, Inc.

المساهمون: Laura Huppert, MD, BA, Principal Investigator

المصدر: Phase II Open-label Study of ARX788 (Anti-HER2 Antibody Drug Conjugate (ADC)) for Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer